Pharmacokinetics of Dasatinib
Tyrosine kinase inhibitors have recently become an essential tool in management of chronic myeloid leukaemia (CML). Dasatinib, a representative of those drugs, acts by inhibiting key proteins included in CML development, predominantly Bcr-Abl and Src. Its advantage is that it shows activity in many...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karolinum Press
2019-10-01
|
| Series: | Prague Medical Report |
| Subjects: | |
| Online Access: | https://pmr.lf1.cuni.cz/120/2/0052/ |